{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:32:41Z","timestamp":1789680761220,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle metabolism characterized by generalized muscle rigidity, increased body temperature, rhabdomyolysis, hyperkalemia and severe metabolic acidosis. The underlying mechanism of MH involves excessive Ca\n                    <jats:sup>2+<\/jats:sup>\n                    release from myotubes via the ryanodine receptor type 1 (RYR1) and the voltage-dependent L-type calcium channel (CACNA1S). As more than 300 variants of unknown significance have been detected to date, we examined whether freely available pathogenicity prediction tools are able to detect relevant MH causing variants. In this diagnostic accuracy study, blood samples from 235 individuals with a history of a clinical malignant hyperthermia or their close relatives were genetically screened for\n                    <jats:italic>RYR1<\/jats:italic>\n                    variants of all 106\n                    <jats:italic>RYR1<\/jats:italic>\n                    exons and additionally for known variants of\n                    <jats:italic>CACNA1S<\/jats:italic>\n                    . In vitro contracture tests were conducted on muscle biopsies obtained from all individuals, independently of whether a pathogenic variant, a variant of unknown significance or no variant was detected. Comparisons were made to three established bioinformatic pathogenicity detection tools to identify the clinical impact of the variants of unknown significance. All detected genetic variants were tested for pathogenicity by three in silico approaches and compared to the in vitro contracture test. Sensitivity and specificity of exon screening of all individuals listed in our MH database was analyzed. Exon screening identified 97 (41%) of the 235 individuals as carriers of pathogenic variants. Variants of unknown significance were detected in 21 individuals. Variants of unknown significance were subdivided into 19 malignant-hyperthermia-susceptible individuals and 2 non-malignant-hyperthermia-susceptible individuals. All pathogenic variants as well as the malignant-hyperthermia-suspectible variants were correctly identified by the bioinformatic prediction tools. Sensitivity of in silico approaches ranged between 0.71 and 0.98 (Polyphen 0.94 [CI 95% 0.75; 0.99]; Sift 0.98 [CI 95% 0.81; 0.99]; MutationTaster 0.92 [CI 95% 0.75; 0.99]). Specificity differed depending on the used tool (Polphen 0.98 [CI 95% 0.32; 0.99]; Sift 0.98 [CI 95% 0.32; 0.99]; MutationTaster 0.00 [CI 95% 0.00; 0.60]). All pathogenic variants and variants of unknown significance were scored as probably damaging in individuals, demonstrating a high sensitivity. Specificity was very low in one of the three tested programs. However, due to potential genotype\u2013phenotype discordance, bioinformatic prediction tools are currently of limited value in diagnosing pathogenicity of MH-susceptible variants.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-82024-7","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T16:23:32Z","timestamp":1612887812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Relevance of pathogenicity prediction tools in human RYR1 variants of unknown significance"],"prefix":"10.1038","volume":"11","author":[{"given":"Kerstin","family":"Hoppe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jurkat-Rott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kranepuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wearing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Heiderich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Merlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"82024_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/bja\/aer132","volume":"107","author":"PM Hopkins","year":"2011","unstructured":"Hopkins, P. M. Malignant hyperthermia: pharmacology of triggering. Br. J. Anaesthes. 107, 48\u201356 (2011).","journal-title":"Br. J. Anaesthes."},{"key":"82024_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1213\/ANE.0b013e3181b5ae2d","volume":"109","author":"W Klingler","year":"2009","unstructured":"Klingler, W., Rueffert, H., Lehmann-Horn, F., Girard, T. & Hopkins, P. M. Core myopathies and risk of malignant hyperthermia. Anesth. Analg. 109, 1167\u20131173 (2009).","journal-title":"Anesth. Analg."},{"key":"82024_CR3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0889-8537(02)00011-1","volume":"20","author":"HK Rosenbaum","year":"2002","unstructured":"Rosenbaum, H. K. & Miller, J. D. Malignant hyperthermia and myotonic disorders. Anesth. Clin. N. Am. 20, 623\u2013664 (2002).","journal-title":"Anesth. Clin. N. Am."},{"key":"82024_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/pan.12224","volume":"23","author":"BW Brandom","year":"2013","unstructured":"Brandom, B. W. & Muldoon, S. M. Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients. Pediatric Anesthesia 23, 851\u2013854 (2013).","journal-title":"Pediatric Anesthesia"},{"key":"82024_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/bja\/aew065","volume":"117","author":"AH Schiemann","year":"2016","unstructured":"Schiemann, A. H. & Stowell, K. M. Comparison of pathogenicity prediction tools on missense variants in RyR1 and CACNA1S associated with malignant hyperthermia. Br. J. Anaesth. 117, 124\u2013128 (2016).","journal-title":"Br. J. Anaesth."},{"key":"82024_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D","volume":"15","author":"TV McCarthy","year":"2000","unstructured":"McCarthy, T. V., Quane, K. A. & Lynch, P. J. Ryandoine receptor mutations in malignant hyperthermia and central core disease. Hum. Mut. 15, 410\u2013417 (2000).","journal-title":"Hum. Mut."},{"key":"82024_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/0888-7543(92)90042-Q","volume":"13","author":"EF Gillard","year":"1992","unstructured":"Gillard, E. F. et al. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 13, 1247\u20131254 (1992).","journal-title":"Genomics"},{"key":"82024_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/ALN.0000000000001877","volume":"128","author":"RS Litman","year":"2018","unstructured":"Litman, R. S. et al. Malignant hyperthermia susceptible and related disease. Anesthesiology 128, 159\u2013167 (2018).","journal-title":"Anesthesiology"},{"key":"82024_CR9","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2217\/14622416.9.11.1657","volume":"9","author":"KM Stowell","year":"2008","unstructured":"Stowell, K. M. Malignant hyperthermia: a pharmacogenetic disorder. Pharmocogenetics 9, 1657\u20131672 (2008).","journal-title":"Pharmocogenetics"},{"key":"82024_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bja\/aev225","volume":"115","author":"PM Hopkins","year":"2015","unstructured":"Hopkins, P. M. et al. European maligant hyperthermia group: the European malignant hyperthermia group guidelines for the investigation of malignant hyperthermia susceptibility. Br. J. Anaesth. 115, 531\u2013539 (2015).","journal-title":"Br. J. Anaesth."},{"key":"82024_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/bja\/aex042","volume":"118","author":"A Merritt","year":"2017","unstructured":"Merritt, A. et al. Assessing the pathogenicity of RyR1 variants in malignant hyperthermia. Br. J. Anaesth. 118, 533\u2013543 (2017).","journal-title":"Br. J. Anaesth."},{"key":"82024_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"82024_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standard and guidelines for the interpretation of sequence variants: a joint consesnsus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"82024_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ejhg.2015.226","volume":"24","author":"G Matthijs","year":"2016","unstructured":"Matthijs, G. et al. Guidelines for diagnostic next generation sequencing. Eur. J. Hum. Genet. 24, 2\u20135 (2016).","journal-title":"Eur. J. Hum. Genet."},{"key":"82024_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"82024_CR16","first-page":"1","volume":"15","author":"N Abhishek","year":"2019","unstructured":"Abhishek, N. & Mauno, V. How good are pathogenicity predictors in detecting benign variants?. PLoS Comput. Biol. 15, 1\u201317 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"82024_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/humu.20939","volume":"30","author":"PN Valdmanis","year":"2009","unstructured":"Valdmanis, P. N., Verlaan, D. J. & Rouleau, G. A. The proportion of mutations predicted to have a deleterious effect differs between gain and loss of function genes in neurodegenerative disease. Hum. Mutat. 30, 481\u2013489 (2009).","journal-title":"Hum. Mutat."},{"key":"82024_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1423-0127-16-42","volume":"16","author":"CG Doss","year":"2009","unstructured":"Doss, C. G. & Sethumadhavan, R. Investigation on the role of nsSNPs in HNPCC genes: a bioinformatics approach. J. Biomed. Sci. 16, 42 (2009).","journal-title":"J. Biomed. Sci."},{"key":"82024_CR19","doi-asserted-by":"publisher","first-page":"E575","DOI":"10.1002\/humu.20991","volume":"1057","author":"A Zullo","year":"2009","unstructured":"Zullo, A. et al. Functional characterization of ryanodine receptor (RyR1) sequence variants using a metabolic assay in immortalized B-lymphocytes. Hum. Mutat. 1057, E575\u2013E590 (2009).","journal-title":"Hum. Mutat."},{"key":"82024_CR20","doi-asserted-by":"publisher","first-page":"33372","DOI":"10.1038\/srep33372","volume":"6","author":"K Hoppe","year":"2016","unstructured":"Hoppe, K. et al. Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals. Sci. Rep. 6, 33372 (2016).","journal-title":"Sci. Rep."},{"key":"82024_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/j.1399-6576.1997.tb04820.x","volume":"41","author":"H Ording","year":"1997","unstructured":"Ording, H. In vitro contracture test for the diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European malignant hyperthermia group. Acta Anaesth. Scand. 41, 955\u2013966 (1997).","journal-title":"Acta Anaesth. Scand."},{"key":"82024_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/aas.12126","volume":"57","author":"K Hoppe","year":"2013","unstructured":"Hoppe, K., Lehmann, H., Chaiklieng, S., Jurkat-Rott, K. & Klingler, W. In vitro muscle contracture investigations on malignant hyperthermia like episodes in myotonia congenital. Acta Anesth. Scand. 57, 1017\u20131023 (2013).","journal-title":"Acta Anesth. Scand."},{"key":"82024_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/ALN.0b013e3182a8a998","volume":"119","author":"JH Kim","year":"2013","unstructured":"Kim, J. H., Jarvik, G. P. & Browning, B. L. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology 119, 1054\u20131065 (2013).","journal-title":"Anesthesiology"},{"key":"82024_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1373\/49.5.761","volume":"49","author":"A Tammaro","year":"2003","unstructured":"Tammaro, A. et al. Scanning for mutations of the ryandine receptor (RYR1) gene by denaturing HPLC: detection of three novel malignant hyperthermia alleles. Clin. Chem. 49, 761\u2013768 (2003).","journal-title":"Clin. Chem."},{"key":"82024_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.ejhg.5200964","volume":"11","author":"RL Robinson","year":"2003","unstructured":"Robinson, R. L. et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?. Eur. J. Hum. Gen. 11, 342\u2013348 (2003).","journal-title":"Eur. J. Hum. Gen."},{"key":"82024_CR26","doi-asserted-by":"publisher","first-page":"26332","DOI":"10.1074\/jbc.272.42.26332","volume":"272","author":"J Tong","year":"1997","unstructured":"Tong, J. et al. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and\/or central core disease. J. Biol. Chem. 272, 26332\u201326339 (1997).","journal-title":"J. Biol. Chem."},{"key":"82024_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/humu.10098","volume":"20","author":"R Robinson","year":"2002","unstructured":"Robinson, R., Brooks, C. & Brown, S. L. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum. Mutat. 20, 88\u201397 (2002).","journal-title":"Hum. Mutat."},{"key":"82024_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/humu.1203","volume":"18","author":"T Girad","year":"2001","unstructured":"Girad, T. et al. Genotype\u2013phenotype comparison of the Swiss malignant hyperthermia population. Hum. Mutat. 18, 357\u2013364 (2001).","journal-title":"Hum. Mutat."},{"key":"82024_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/nar\/gkg088","volume":"31","author":"PC Ng","year":"2003","unstructured":"Ng, P. C. & Henikoff, S. SIFT: predicting amnio acid changes that affect protein function. Nucleic Acids Res. 31, 13 (2003).","journal-title":"Nucleic Acids Res."},{"key":"82024_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar, P., Henikoff, S. & Ng, P. C. Prediciting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073\u20131081 (2009).","journal-title":"Nat. Protoc."},{"key":"82024_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249 (2010).","journal-title":"Nat. Methods"},{"key":"82024_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nmeth0810-575","volume":"7","author":"JM Schwarz","year":"2010","unstructured":"Schwarz, J. M., R\u00f6delsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7, 575\u2013576 (2010).","journal-title":"Nat. Methods"},{"key":"82024_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth.2890","volume":"11","author":"JM Schwarz","year":"2014","unstructured":"Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361\u2013361 (2014).","journal-title":"Nat. Methods"},{"key":"82024_CR34","doi-asserted-by":"publisher","first-page":"e1004725","DOI":"10.1371\/journal.pcbi.1004725","volume":"12","author":"DL Masica","year":"2016","unstructured":"Masica, D. L. & Karchin, R. Towards Increasing the clinical relevance of in silico methods to predict pathogenic missense variants. PLoS Comp. Biol. 12, e1004725 (2016).","journal-title":"PLoS Comp. Biol."},{"key":"82024_CR35","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nmeth.2832","volume":"11","author":"GR Ritchie","year":"2014","unstructured":"Ritchie, G. R., Dunham, I., Zeggini, E. & Flicek, P. Functional annotation of noncoding sequence variants. Nat. Methods 11, 294\u2013296 (2014).","journal-title":"Nat. Methods"},{"key":"82024_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/gtmb.2010.0036","volume":"14","author":"SE Flanagan","year":"2010","unstructured":"Flanagan, S. E., Patch, A. M. & Ellard, S. Using SIFT and polyphen to predict loss-of-function and gain-of-function mutations. Genet. Test. Mol. Biomark. 14, 533\u2013537 (2010).","journal-title":"Genet. Test. Mol. Biomark."},{"key":"82024_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/ALN.0000000000001878","volume":"128","author":"S Riazi","year":"2018","unstructured":"Riazi, S., Kraeva, N. & Hopkins, P. M. Malignant Hyperthermia in the post-genomics Era: new perspectives on an old concept. Anesthesiology 128, 168\u2013180 (2018).","journal-title":"Anesthesiology"},{"key":"82024_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/ajcp\/93.2.252","volume":"93","author":"PN Valenstein","year":"1990","unstructured":"Valenstein, P. N. Evalating diagnostic tests with imperfect standards. Am. J. Clin. Pathol. 93, 252\u2013258 (1990).","journal-title":"Am. J. Clin. Pathol."},{"key":"82024_CR39","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1213\/ANE.0b013e3181b5ae2d","volume":"109","author":"W Klingler","year":"2009","unstructured":"Klingler, W., Rueffert, H. & Lehmann-Horn, F. Core myopathies and risk of malignant hyperthermia. Anesth. Anlag. 109, 1167\u20131173 (2009).","journal-title":"Anesth. Anlag."},{"key":"82024_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D","volume":"15","author":"TV McCarthy","year":"2000","unstructured":"McCarthy, T. V., Quane, K. A. & Lynch, P. J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum. Mutat. 15, 410\u2013417 (2000).","journal-title":"Hum. Mutat."},{"key":"82024_CR41","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/humu.20356","volume":"27","author":"R Robinson","year":"2009","unstructured":"Robinson, R., Carpenter, D., Shaw, M. A., Halsall, J. & Hopkins, P. Mutation in RyR1 in malignant hyperthermia and central core disease. Hum. Mutat. 27, 977\u2013989 (2009).","journal-title":"Hum. Mutat."},{"key":"82024_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D","volume":"23","author":"K Jurkat-Rott","year":"2000","unstructured":"Jurkat-Rott, K., McCarthy, T. & Lehmann-Horn, F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23, 4\u201317 (2000).","journal-title":"Muscle Nerve"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82024-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T22:28:31Z","timestamp":1670020111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82024"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82024-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"12 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3445"}}